Skip to main content

Table 2 Univariate and Multivariable Cox Proportional Hazard Models of PFS vs BMI

From: The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

  

anti-CTLA-4

anti-PD-1

Combination

  

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Univariate Model

Overweight (vs Normal BMI)

1.1(0.67,1.83)

0.7

1.58(0.78,3.19)

0.21

0.36(0.15,0.85)

0.02

Obesity (vs Normal BMI)

0.98(0.59,1.63)

0.93

1.49(0.71,3.13)

0.3

0.17(0.04,0.65)

0.01

Multivariable Model

Overweight (vs Normal BMI)

0.97(0.56,1.69)

0.92

2.34(1.05,5.2)

0.04

0.5(0.15,1.71)

0.27

Obesity (vs Normal BMI)

1.16(0.7,1.94)

0.57

2.46(1.03,5.89)

0.04

0.18(0.05,0.74)

0.02

Female

0.94(0.59,1.51)

0.81

1.05(0.6,1.84)

0.85

1.8(0.72,4.49)

0.21

Age at Treatment Initiation

1(0.98,1.01)

0.77

0.99(0.97,1.01)

0.28

0.99(0.95,1.03)

0.67

Stage IV at Treatment Initiation(vs Stage III)

3(1.07,8.41)

0.04

0.88(0.3,2.64)

0.82

0.19(0.02,1.62)

0.13

ECOG Status

1.78(1.22,2.6)

0.003

2.67(1.65,4.31)

0.003

3.02(1.44,6.32)

<.001

LDH High

1.16(0.74,1.82)

0.52

2.25(1.08,4.7)

0.03

1.45(0.65,3.23)

0.36

Number of Metastatic Sites

1.21(1.04,1.4)

0.02

1.11(0.91,1.36)

0.29

0.94(0.7,1.25)

0.68

BRAF Mutated

0.86(0.37,2)

0.73

0.43(0.12,1.6)

0.21

1.83(0.61,5.54)

0.28